YB new stock pitches (Tue, Aug 4)

Vistance Networks (NASDAQ: VISN), which the author owns via a call spread to avoid tying up capital for what may take a year to rerate or sell, trades at $11.83 against roughly $8.31/share (~$1.88 billion) in cash and zero debt after selling its Ruckus enterprise networking business to Belden on July 1 for $1.846 billion (~$1.75 billion net proceeds). Formerly a debt-funded cable/copper roll-up ($3B BNS from TE Connectivity in 2015, $7B Arris in 2019) that peaked at $10.5 billion of debt at 7.1x net leverage and fell from over $40 in 2018 to under $1 by 2024, the board began selling in pieces—Connectivity and Cable Solutions to Amphenol for $10.5 billion in January 2026 (repaying all debt, redeeming Series A preferred, and paying a $10.00/share special distribution on April 27)—leaving one segment, Aurora Networks. The market values Aurora at just $3.52/share (~$790 million EV, or <4x EBITDA—3.3x on the guidance midpoint, 3.9x on annualized Q1), despite Q1 2026 revenue of $298.4 million (up 33%), adjusted EBITDA of $50.3 million, and 2026 adjusted EBITDA guidance of $225–250 million. The catalyst is a promised dividend distributing a significant portion of net proceeds within 60 days of closing (by August 30), with the amount likely revealed at Q2 results on August 6; management previously declared $10.00/share on April 7 and paid it 20 days later. At 8x guidance Aurora is worth ~$8/share, and up to 12x (~$12) if a strategic buyer emerges. Risks/considerations: the distribution is labeled a dividend (retained earnings turned positive $2.45 billion on the CCS gain), so it is likely taxable as a dividend rather than return of capital, arguing for holding in an IRA; and the large special distribution will likely trigger an OCC contract adjustment reducing option strikes on the ex-date, complicating covered-call strategies. The author frames this as low-downside, getting the Aurora stub for a steal, not a multibagger.

Read the full article here. Read time: 3 min

Flowers Foods (FLO), the worst-performing US consumer packaged goods name, is a new position for the author as a special situations play driven by forced selling from its deletion from the high yield dividend aristocrat index and mid/small cap indexes, plus dividend and ETF liquidations following its May 2026 dividend cut (with possible year-end tax loss selling ahead). Leverage spiked from 1.9x in 2022 to 3.4x in 2026, largely due to the $795 million Simple Mills acquisition—a healthier-trend bakery brand meant to drive growth as traditional bread slows—which impaired debt metrics but was funded with cash, not stock (consistent with decades of not issuing shares for acquisitions). Management confirmed on the Q1 call that dividend-cut proceeds will reduce debt, targeting $300 million of debt reduction by 2027 (corroborated by S&P Global) and sub-3x leverage by year-end 2027; the company retains its investment grade rating, was removed from Credit Watch, and has little debt risk between a 2026 maturity (to be refinanced at a higher rate) and its 2.4% $496 million maturity due in 2031. FLO holds the #1 most sold US bread loaf (Nature's Own) and dominant share in gluten-free and organic bread, trading at the lowest multiple in the US CPG space with a record 15-20% free cash flow yield, suggesting bad news is priced in or amplified. The author argues bread is not going extinct (71% of Americans buy bread annually, 31% of bread eaten is white bread, average consumption 17-24 kg/year) and that Ozempic/GLP-1 drugs are altering rather than disrupting the category, while the defensive, cheap, staple nature of bread supports resilience. Key risks include elevated ~6x net debt/free cash flow, sector-wide multiple contraction and weakness (General Mills' CEO calls it the worst period of his career), inverse trading with AI/momentum themes, and a possible second dividend cut in a worst-case scenario. It is not the author's highest conviction position, but the risk-reward is viewed as good, and the author has added on dips over the past week.

Read the full article here. Read time: 6 min

TOI (The Oncology Institute) is a long position ahead of Q2 earnings next Thursday, positioned as an oncology value-based care (VBC) play whose dispensary segment is printing FCF and growing fast. FY26 guidance screens as barely profitable, with ~$640M revenue and $0-9M adjusted EBITDA at a $560M EV. Long term, the thesis is that at scale oncology VBC players gain enough operating leverage to absorb the large drug-pricing volatility inherent in oncology, where a bad drug year barely dents a large book; TOI starts from attractive markets (mainly Florida) with possible further expansion to be announced on the Q2 call. The near-term limitation—individual oncology books being too actuarially small and noisy, with drugs dominating spend—favors TOI's pathways and dispensing over raw risk-taking, but is self-correcting since payers desperate to delegate oncology as drug trend inflates deliver the volume that makes capitation work later (a flywheel). The business runs three lines: low-margin FFS (~20%), capitation (~30%, blended MLR low 80s), and an owned specialty pharmacy (~50% of mix, 18% GM retaining Part D drug economics), blending to ~17% gross margin, reconciling to the reported ~16% today. The key insight is that a capitated life is the customer acquisition event, not the profit, since the capitation rate barely moves ($50 to $54 PMPM over three years) while scripts per cohort triple (1.0 to 3.2), lifting gross profit per 1,000 capitated lives ~68% (from $9,949 to $16,685) with no rate increase. Combined with visible operating leverage—SG&A down from 30% of revenue in early 2024 to 19% by Q1 2026—a normalized EBITDA margin of ~5-6% (~$35M on the current base) is sensible, implying ~16x normalized for a business guided to grow revenue near 20% annually, with further IRA-driven pharmacy margin squeeze only increasing capitation demand and operating leverage.

Read the full article here. Read time: 2 min